Role of the Toll Like Receptor (TLR) Radical Cycle in Chronic Inflammation: Possible Treatments Targeting the TLR4 Pathway
Identifieur interne : 001121 ( Main/Exploration ); précédent : 001120; suivant : 001122Role of the Toll Like Receptor (TLR) Radical Cycle in Chronic Inflammation: Possible Treatments Targeting the TLR4 Pathway
Auteurs : Kurt Lucas [Allemagne] ; Michael Maes [Thaïlande, Pays-Bas, Australie]Source :
- Molecular Neurobiology [ 0893-7648 ] ; 2013-08-01.
English descriptors
- KwdEn :
Abstract
Abstract: Activation of the Toll-like receptor 4 (TLR4) complex, a receptor of the innate immune system, may underpin the pathophysiology of many human diseases, including asthma, cardiovascular disorder, diabetes, obesity, metabolic syndrome, autoimmune disorders, neuroinflammatory disorders, schizophrenia, bipolar disorder, autism, clinical depression, chronic fatigue syndrome, alcohol abuse, and toluene inhalation. TLRs are pattern recognition receptors that recognize damage-associated molecular patterns and pathogen-associated molecular patterns, including lipopolysaccharide (LPS) from gram-negative bacteria. Here we focus on the environmental factors, which are known to trigger TLR4, e.g., ozone, atmosphere particulate matter, long-lived reactive oxygen intermediate, pentachlorophenol, ionizing radiation, and toluene. Activation of the TLR4 pathways may cause chronic inflammation and increased production of reactive oxygen and nitrogen species (ROS/RNS) and oxidative and nitrosative stress and therefore TLR-related diseases. This implies that drugs or substances that modify these pathways may prevent or improve the abovementioned diseases. Here we review some of the most promising drugs and agents that have the potential to attenuate TLR-mediated inflammation, e.g., anti-LPS strategies that aim to neutralize LPS (synthetic anti-LPS peptides and recombinant factor C) and TLR4/MyD88 antagonists, including eritoran, CyP, EM-163, epigallocatechin-3-gallate, 6-shogaol, cinnamon extract, N-acetylcysteine, melatonin, and molecular hydrogen. The authors posit that activation of the TLR radical (ROS/RNS) cycle is a common pathway underpinning many “civilization” disorders and that targeting the TLR radical cycle may be an effective method to treat many inflammatory disorders.
Url:
DOI: 10.1007/s12035-013-8425-7
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000776
- to stream Istex, to step Curation: 000772
- to stream Istex, to step Checkpoint: 000272
- to stream Main, to step Merge: 001122
- to stream Main, to step Curation: 001121
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Role of the Toll Like Receptor (TLR) Radical Cycle in Chronic Inflammation: Possible Treatments Targeting the TLR4 Pathway</title><author><name sortKey="Lucas, Kurt" sort="Lucas, Kurt" uniqKey="Lucas K" first="Kurt" last="Lucas">Kurt Lucas</name></author><author><name sortKey="Maes, Michael" sort="Maes, Michael" uniqKey="Maes M" first="Michael" last="Maes">Michael Maes</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:A8519E15E7FED410BE9879F767D24DC9E2A526B3</idno><date when="2013" year="2013">2013</date><idno type="doi">10.1007/s12035-013-8425-7</idno><idno type="url">https://api.istex.fr/ark:/67375/VQC-PJ7C3JPB-6/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000776</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000776</idno><idno type="wicri:Area/Istex/Curation">000772</idno><idno type="wicri:Area/Istex/Checkpoint">000272</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000272</idno><idno type="wicri:doubleKey">0893-7648:2013:Lucas K:role:of:the</idno><idno type="wicri:Area/Main/Merge">001122</idno><idno type="wicri:Area/Main/Curation">001121</idno><idno type="wicri:Area/Main/Exploration">001121</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Role of the Toll Like Receptor (TLR) Radical Cycle in Chronic Inflammation: Possible Treatments Targeting the TLR4 Pathway</title><author><name sortKey="Lucas, Kurt" sort="Lucas, Kurt" uniqKey="Lucas K" first="Kurt" last="Lucas">Kurt Lucas</name><affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Sportzenkoppel 54, 22359, Hamburg</wicri:regionArea><placeName><settlement type="city">Hambourg</settlement><region type="land" nuts="2">Hambourg</region></placeName></affiliation></author><author><name sortKey="Maes, Michael" sort="Maes, Michael" uniqKey="Maes M" first="Michael" last="Maes">Michael Maes</name><affiliation wicri:level="1"><country xml:lang="fr">Thaïlande</country><wicri:regionArea>Piyavate Hospital, Bangkok</wicri:regionArea><wicri:noRegion>Bangkok</wicri:noRegion></affiliation><affiliation wicri:level="1"><country xml:lang="fr">Thaïlande</country><wicri:regionArea>Department of Psychiatry, Chulalongkorn University, Por Bor Ror Building 12, Bangkok</wicri:regionArea><wicri:noRegion>Bangkok</wicri:noRegion></affiliation><affiliation wicri:level="1"><country xml:lang="fr" wicri:curation="lc">Pays-Bas</country><wicri:regionArea>International PNI Reference Center, Roosendaal</wicri:regionArea><wicri:noRegion>Roosendaal</wicri:noRegion></affiliation><affiliation wicri:level="1"><country xml:lang="fr">Australie</country><wicri:regionArea>Department of Psychiatry, Deakin University, Geelong</wicri:regionArea><wicri:noRegion>Geelong</wicri:noRegion></affiliation><affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Molecular Neurobiology</title><title level="j" type="abbrev">Mol Neurobiol</title><idno type="ISSN">0893-7648</idno><idno type="eISSN">1559-1182</idno><imprint><publisher>Springer US; http://www.springer-ny.com</publisher><pubPlace>Boston</pubPlace><date type="published" when="2013-08-01">2013-08-01</date><biblScope unit="volume">48</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="190">190</biblScope><biblScope unit="page" to="204">204</biblScope></imprint><idno type="ISSN">0893-7648</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0893-7648</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Chronic fatigue</term><term>Cytokines</term><term>Depression</term><term>Inflammation</term><term>LPS</term><term>Oxidative and nitrosative stress</term><term>Toll-like receptor</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Abstract: Activation of the Toll-like receptor 4 (TLR4) complex, a receptor of the innate immune system, may underpin the pathophysiology of many human diseases, including asthma, cardiovascular disorder, diabetes, obesity, metabolic syndrome, autoimmune disorders, neuroinflammatory disorders, schizophrenia, bipolar disorder, autism, clinical depression, chronic fatigue syndrome, alcohol abuse, and toluene inhalation. TLRs are pattern recognition receptors that recognize damage-associated molecular patterns and pathogen-associated molecular patterns, including lipopolysaccharide (LPS) from gram-negative bacteria. Here we focus on the environmental factors, which are known to trigger TLR4, e.g., ozone, atmosphere particulate matter, long-lived reactive oxygen intermediate, pentachlorophenol, ionizing radiation, and toluene. Activation of the TLR4 pathways may cause chronic inflammation and increased production of reactive oxygen and nitrogen species (ROS/RNS) and oxidative and nitrosative stress and therefore TLR-related diseases. This implies that drugs or substances that modify these pathways may prevent or improve the abovementioned diseases. Here we review some of the most promising drugs and agents that have the potential to attenuate TLR-mediated inflammation, e.g., anti-LPS strategies that aim to neutralize LPS (synthetic anti-LPS peptides and recombinant factor C) and TLR4/MyD88 antagonists, including eritoran, CyP, EM-163, epigallocatechin-3-gallate, 6-shogaol, cinnamon extract, N-acetylcysteine, melatonin, and molecular hydrogen. The authors posit that activation of the TLR radical (ROS/RNS) cycle is a common pathway underpinning many “civilization” disorders and that targeting the TLR radical cycle may be an effective method to treat many inflammatory disorders.</div></front></TEI><affiliations><list><country><li>Allemagne</li><li>Australie</li><li>Pays-Bas</li><li>Thaïlande</li></country><region><li>Hambourg</li></region><settlement><li>Hambourg</li></settlement></list><tree><country name="Allemagne"><region name="Hambourg"><name sortKey="Lucas, Kurt" sort="Lucas, Kurt" uniqKey="Lucas K" first="Kurt" last="Lucas">Kurt Lucas</name></region></country><country name="Thaïlande"><noRegion><name sortKey="Maes, Michael" sort="Maes, Michael" uniqKey="Maes M" first="Michael" last="Maes">Michael Maes</name></noRegion><name sortKey="Maes, Michael" sort="Maes, Michael" uniqKey="Maes M" first="Michael" last="Maes">Michael Maes</name></country><country name="Pays-Bas"><noRegion><name sortKey="Maes, Michael" sort="Maes, Michael" uniqKey="Maes M" first="Michael" last="Maes">Michael Maes</name></noRegion></country><country name="Australie"><noRegion><name sortKey="Maes, Michael" sort="Maes, Michael" uniqKey="Maes M" first="Michael" last="Maes">Michael Maes</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/StressCovidV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001121 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001121 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= StressCovidV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:A8519E15E7FED410BE9879F767D24DC9E2A526B3
|texte= Role of the Toll Like Receptor (TLR) Radical Cycle in Chronic Inflammation: Possible Treatments Targeting the TLR4 Pathway
}}
| This area was generated with Dilib version V0.6.33. |  |